Dual PI3K/BET inhibition as a therapeutic strategy in T cell lymphoma

Name: Dr Danielle Oh
Partner Organisation: Monash Health, Hudson Institute of Medical Research
Project Start Date: June 1, 2024
THIS PROJECT IS NOW COMPLETE
Aims:
T-cell lymphomas are rare blood cancers that are difficult to treat and many patients do not respond well to existing therapies. This STAR Fellowship project investigated a new experimental drug 18DS, designed to block two pathways cancer cells use to grow and survive. The research aims were to determine whether 18DS could be effective against T-cell lymphomas, and to better understand how the drug works, to help guide the development of future treatments.
Outcomes:
In laboratory studies, 18DS was highly effective at killing T-cell lymphoma cells and worked better than drugs that target only one cancer pathway. Further studies identified several important biological pathways that may influence how well the 18DS works, and how cancer cells develop resistance. The researchers also tested 18DS in breast cancer models, and it showed strong anti-cancer effects and significantly improved survival in mice, suggesting that it may have strong potential as a treatment for some types of breast cancer.
Research translation and Impact:
This research has provided important new insights into T-cell lymphoma and the potential of 18DS as a future cancer treatment. The findings have helped researchers better understand why some cancer cells respond to treatment while others may become resistant. The research team is now carrying out further studies to identify which patients may be most likely to benefit from 18DS and whether it could be used together with other treatments to improve its effectiveness. The promising results seen in breast cancer studies also suggest that 18DS may have potential for treating other types of cancer.
This research is supported by the Bill Long Charitable Trust, The Dean William Winter Trust, Estate of Harry Bunting, A J Anderson Charitable Trust – Dorothy Hill Memorial Trust Fund, William & Evelyn Beveridge Settlement, and the Beatrice Harris Charitable Trust (Equity Trustees).
